Development and in vitro evaluation of a copper-64 radiolabeled antibody for targeting the CXCR4 receptor in human multiple myeloma - Université de Bretagne Occidentale
Article Dans Une Revue Nuclear Medicine and Biology Année : 2022

Development and in vitro evaluation of a copper-64 radiolabeled antibody for targeting the CXCR4 receptor in human multiple myeloma

Domaines

Chimie
Fichier non déposé

Dates et versions

hal-04545853 , version 1 (14-04-2024)

Identifiants

Citer

Cassandra Métivier, Patricia Le Saec, Hela Bouhsine, Séverine Marionneau-Lambot, Emmanuel Garçion, et al.. Development and in vitro evaluation of a copper-64 radiolabeled antibody for targeting the CXCR4 receptor in human multiple myeloma. Nuclear Medicine and Biology, 2022, 108-109, pp.S203-S204. ⟨10.1016/S0969-8051(22)00419-X⟩. ⟨hal-04545853⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

More